Lung Cancer Trials Ask AI to find trials
TerminatedPhase 1NCT03854227
Official study title

A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

Study summary

This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedPF-06939999 dose escalation and PF-06939999 monotherapy

Plus 1 other study approaches.

Who it may be forMetastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 13, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?22 U.S. locations

Locations may change over time.

Who runs it?Pfizer

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Pfizer
Interventions being studied
Drug: PF-06939999 dose escalation; Drug: PF-06939999 monotherapy; Drug: PF-06939999 in combination with docetaxel
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting
Metastatic or stage IV→
Treatment approach
Chemotherapy→
Study topics
After prior treatment→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Histologically or cytologically confirmed locally advanced or metastatic NSCLC, urothelial carcinoma or HNSCC
  • Progressed after at least 1 line of treatment and no more than 3 lines of treatment
  • At least one measurable lesion as defined by RECIST version 1.1
  • ECOG Performance Status 0 or 1
  • Adequate Bone Marrow Function
  • Adequate Renal Function
  • Adequate Liver Function
  • Resolved acute effects of any prior therapy
Reasons someone may not be able to joinExclusion criteria
  • Known active uncontrolled or symptomatic CNS metastases.
  • Major surgery, radiation therapy, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry.
  • Active, uncontrolled infection, including COVID-19
  • Known or suspected hypersensitivity to PF-06939999
  • Inability to consume or absorb study drug

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Scottsdale Healthcare Hospitals d/b/a HonorHealthScottsdale, Arizona
  • Virginia G. Piper Cancer PharmacyScottsdale, Arizona
  • Keck Hospital of USCLos Angeles, California
  • LAC + USC Medical CenterLos Angeles, California
  • USC Norris Comprehensive Cancer CenterLos Angeles, California
  • USC/Norris Comprehensive Cancer CenterLos Angeles, California
  • Keck Medical Center of USC PasadenaPasadena, California
  • AdventHealth Celebration Infusion CenterCelebration, Florida
  • AdventHealth Medical Group Oncology Research at CelebrationCelebration, Florida
  • University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer CenterMiami, Florida
  • AdventHealth Orlando - Investigational Drug ServicesOrlando, Florida
  • AdventHealth Orlando Infusion CenterOrlando, Florida

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 13, 2025. Always confirm current availability with the study team.

View original record ↗